Scottsdale, AZ – December 13, 2019 –Universal Health Therapeutics, an AI-based biopharmaceutical company, is presenting a poster at the San Antonio Breast Cancer Symposium 2019.  The poster will highlight ErSO, an orally bioavailable, first-in-class therapy for the treatment of resistant ER alpha positive breast cancer.  ErSO triggers an immunogenic necrotic cell death via a novel hyperactivation of the anticipatory Unfolding Protein Response (a-UPR) without ER alpha degradation.

Full Poster: Quantitative Regression of Estrogen Receptor Alpha Positive Breast Cancer

Session: New Drugs and Mechanisms

Board #: P5-05-16

Time: December 13rd , 2019, 5PM-7PM

###

About Universal Health Therapeutics

Universal Health Therapeutics, LLC (SO) is an AI-based cancer therapy discovery and development company.  SO has a multidisciplinary team of scientists and a revolutionary cognitive computing platform (Expansive.AI) able to intelligently integrate, model, and mine big data from hundreds of molecular, genomic, and biomedical datasets.  This new kind of computational data mining has empowered the SO team to rapidly extract many therapeutically useful insights from complex multi-scalar systems models of cancer biology.  This scalable data-driven approach has been used by SO to translate many unique biological insights into dozens of discovery projects and research collaborations with leading universities, producing one of the fastest growing pipelines of innovative cancer therapies in the industry. For more information, go to www.Healthbridgespeutices.com.

Media Contact
Universal Health Therapeutics
Katy Marhenke
info@Healthbridgespeutices.com